Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

From the wind farms of Jutland to the rising skyline of NEOM, Denmark and Saudi Arabia are edging toward a new phase in their ...

President Trump’s threat to impose 30% tariffs on the European Union disrupted negotiations. From cars to wine, these are the ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

A genetic test may one day predict a child’s risk of obesity in adulthood, paving the way for early interventions.

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...